Premium
Duodeno‐pancreatic neuroendocrine tumours
Author(s) -
PEROS G.,
SAKORAFAS G.H.,
KONSTANTOUDAKIS G.,
GIANNOPOULOS G.A.,
PETROPOULOU K.,
PARASI A.
Publication year - 2010
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/j.1365-2354.2007.00894.x
Subject(s) - medicine , chromogranin a , endocrine system , multiple endocrine neoplasia , glucagonoma , somatostatin , calcitonin , pancreas , neuroendocrine tumors , pancreatic polypeptide , neuroendocrine tumour , carcinoid tumour , pathology , pancreatic cancer , gastroenterology , insulinoma , immunohistochemistry , cancer , hormone , glucagon , biochemistry , chemistry , gene
PEROS G., SAKORAFAS G.H., KONSTANTOUDAKIS G., GIANNOPOULOS G.A., PETROPOULOU K. & PARASI A. (2010) European Journal of Cancer Care 19, 393–402
Duodeno‐pancreatic neuroendocrine Tumours Duodeno‐pancreatic neuroendocrine tumours (DP‐ETs) are increasingly diagnosed today due to the widespread use of modern imaging methods. Duodeno‐pancreatic endocrine tumours should be treated by radical surgical resection, which offers a high chance for cure when the disease is localized. A high index of suspicion is required in these patients for the presence of a multiple endocrine neoplasia type syndrome. We present four patients with DP‐ET surgically treated at our department between 2000 and 2004. Histological/immunohistochemical diagnosis was somatostatin‐producing tumour in the first patient, oncocytic endocrine tumour positive for neurone‐specific enolase and focally for chromogranin in the second patient, glucagonoma and pancreatic polypeptide‐producing endocrine pancreatic tumour in the third patient, and gastrin, somatostatin, calcitonin, insulin and adrenocorticotropic hormone (ACTH)‐producing tumour in the fourth. The second patient died 6.5 years following surgery due to disseminated disease.